HK1246193A1 - 用於改善认知的方法和组合物 - Google Patents

用於改善认知的方法和组合物 Download PDF

Info

Publication number
HK1246193A1
HK1246193A1 HK18105784.9A HK18105784A HK1246193A1 HK 1246193 A1 HK1246193 A1 HK 1246193A1 HK 18105784 A HK18105784 A HK 18105784A HK 1246193 A1 HK1246193 A1 HK 1246193A1
Authority
HK
Hong Kong
Prior art keywords
klotho
individual
cognitive
human
mice
Prior art date
Application number
HK18105784.9A
Other languages
English (en)
Chinese (zh)
Inventor
德娜‧杜波
Original Assignee
加利福尼亚大学董事会
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加利福尼亚大学董事会 filed Critical 加利福尼亚大学董事会
Publication of HK1246193A1 publication Critical patent/HK1246193A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18105784.9A 2015-02-06 2016-02-05 用於改善认知的方法和组合物 HK1246193A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113300P 2015-02-06 2015-02-06
US62/113,300 2015-02-06
PCT/US2016/016842 WO2016127097A1 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition

Publications (1)

Publication Number Publication Date
HK1246193A1 true HK1246193A1 (zh) 2018-09-07

Family

ID=56564770

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105784.9A HK1246193A1 (zh) 2015-02-06 2016-02-05 用於改善认知的方法和组合物

Country Status (8)

Country Link
US (6) US10632180B2 (https=)
EP (2) EP3253403B1 (https=)
JP (1) JP6794363B2 (https=)
CN (2) CN121102455A (https=)
AU (2) AU2016215080B2 (https=)
CA (1) CA2974988A1 (https=)
HK (1) HK1246193A1 (https=)
WO (1) WO2016127097A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
JP2018184369A (ja) * 2017-04-26 2018-11-22 株式会社明治 知的作業能力向上用組成物および認知能力向上用組成物
US12227777B2 (en) * 2018-01-12 2025-02-18 New York University Soluble alpha-Klotho proteins, protein fragments, and uses thereof
WO2019222629A1 (en) * 2018-05-17 2019-11-21 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
CA3120701A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
EP4103223A4 (en) 2020-02-12 2024-05-29 The Regents of the University of California PLATELET FACTORS AND COGNITIVE IMPROVEMENT
US20230123357A1 (en) * 2020-03-04 2023-04-20 The Regents Of The University Of California Use of downstream factors in the klotho pathway to assess klotho activity
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
TW202434279A (zh) * 2022-10-28 2024-09-01 美商聯合生物技術公司 用於改善認知之方法
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗
WO2025168038A1 (en) * 2024-02-07 2025-08-14 Kunming Institute Of Zoology, Chinese Academy Of Sciences Methods and compositions for ameliorating impairment of regenerative and cognitive function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
WO1998029544A1 (en) 1996-12-26 1998-07-09 Kyowa Hakko Kogyo Co., Ltd. Novel peptide, novel dna, and novel antibody
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ATE405286T1 (de) * 2001-03-23 2008-09-15 Chemo Sero Therapeut Res Inst Neue mittel zur linderung von motorischen störungen
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040001859A1 (en) 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
US20100330062A1 (en) 2007-05-08 2010-12-30 Koeffler H Phillip Klotho protein and related compounds for the treatment and diagnosis of cancer
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN101711779B (zh) * 2008-10-08 2012-12-05 中南大学 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途
WO2011084452A1 (en) 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
JP2012184184A (ja) * 2011-03-04 2012-09-27 Nara Medical Univ 抗老化作用を有するヤドリギ抽出物
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Also Published As

Publication number Publication date
US10864256B2 (en) 2020-12-15
US10632180B2 (en) 2020-04-28
US10300117B2 (en) 2019-05-28
US20180015151A1 (en) 2018-01-18
AU2020281046B2 (en) 2024-04-18
US20200230214A1 (en) 2020-07-23
JP2018509393A (ja) 2018-04-05
CA2974988A1 (en) 2016-08-11
AU2020281046A1 (en) 2021-01-07
US11738070B2 (en) 2023-08-29
EP3957317A1 (en) 2022-02-23
WO2016127097A1 (en) 2016-08-11
US20240108698A1 (en) 2024-04-04
EP3253403A4 (en) 2018-09-26
JP6794363B2 (ja) 2020-12-02
US12239694B2 (en) 2025-03-04
US20250161418A1 (en) 2025-05-22
US20180256688A1 (en) 2018-09-13
CN107405382A (zh) 2017-11-28
AU2016215080A1 (en) 2017-08-17
EP3253403A1 (en) 2017-12-13
AU2016215080B2 (en) 2020-12-24
CN121102455A (zh) 2025-12-12
US20210069305A1 (en) 2021-03-11
EP3253403B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
US12239694B2 (en) Methods and compositions for improved cognition
Lee et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy
US20150335764A1 (en) Compositions and Methods for Parkinson's Disease Treatment by BDNF-flag Gene Transfer through Neurotensin Polyplex to Nigral Dopamine Neuro
Shen et al. Novel synaptobrevin‐1 mutation causes fatal congenital myasthenic syndrome
WO2018057825A1 (en) Antigen-specific immune modulation
KR20130113962A (ko) 뉴레굴린 이소형, 뉴레굴린 폴리펩타이드 및 이의 용도
US20240366736A1 (en) Method for managing pain
US20230181691A1 (en) Platelet factors and cognitive improvement
ES2569552T3 (es) Composiciones de péptido de MNTF y métodos de uso
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
EP3920887B1 (en) A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
HK40070785A (en) Methods and compositions for improved cognition
Zhang et al. A humanized Gs-coupled DREADD for circuit and behavior modulation
US20230181687A1 (en) Methods and Compositions for Treatment of Age-Related Dysfunction
WO2026059892A1 (en) Gpx3 as a blood-based calorie restriction mimetic to treat age-related cognitive decline
Yan et al. Mouse behavioral genomics identifies Creld1 as a gatekeeper of somatosensation
CN121666246A (zh) 质子泵调控剂在制备药物中的用途